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Abstract: Acute myeloid leukemia (AML) is a hematologic malignancy characterized by the rapid
and uncontrolled clonal growth of myeloid lineage cells in the bone marrow. The advent of oral,
selective inhibitors of the B-cell leukemia/lymphoma-2 (BCL-2) apoptosis pathway, such as venetoclax,
will likely induce a paradigm shift in the treatment of AML. However, the high cost of this treatment
and the risk of additive toxicity when used in combination with standard chemotherapy represent
limitations to its use and underscore the need to identify which patients are most—and least—likely
to benefit from incorporation of venetoclax into the treatment regimen. Bone marrow specimens
from 93 newly diagnosed AML patients were collected in this study and evaluated for BCL-2 protein
expression by immunohistochemistry. Using this low-cost, easily, and readily applicable analysis
method, we found that 1 in 5 AML patients can be considered as BCL-2−. In addition to a lower
bone marrow blast percentage, this group exhibited a favorable molecular profile characterized by
lower WT1 expression and underrepresentation of FLT3 mutations. As compared to their BCL-2+
counterparts, the absence of BCL-2 expression was associated with a favorable response to standard
chemotherapy and overall survival, thus potentially precluding the necessity for venetoclax add-on.
Keywords: acute myeloid leukemia; immunohistochemistry; BCL-2; venetoclax; FLT3; next-generation
sequencing
1. Introduction
Acute myeloid leukemia (AML) is a hematologic malignancy characterized by the rapid and
uncontrolled clonal growth of myeloid lineage cells in the bone marrow [1]. The standard frontline
treatment for AML comprises a combination of an anthracycline for 3 days and cytarabine for 7 days,
with this “3 + 7” intensive chemotherapy (IC) regimen serving as the backbone of AML treatment
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since the 1970s [2]. During the previous decade, hypomethylating agents (HMAs), such as decitabine
and azacitidine, have complemented the treatment armamentarium for AML. These less intensive
drugs are predominantly used in elderly AML patients or those who are unfit for IC [3].
Even with IC or HMAs, the outcome of AML remains poor, as exemplified by a 5-year overall
survival (OS) rate of 30% [4]. This has led to a search for novel, more effective treatment approaches.
One of these approaches is based on the induction of AML cell apoptosis by inhibiting B-cell
leukemia/lymphoma-2 (BCL-2) [5]. BCL-2 is an anti-apoptotic protein commonly expressed in
hematological malignancies, including AML. In 2018, the US Food and Drug Administration approved
the first oral, selective BCL-2 inhibitor (venetoclax) for use in combination with HMAs in newly
diagnosed AML patients aged ≥75 years and unfit for IC. The results of the pivotal phase III VIALE-A
study investigating the combination of venetoclax and azacitidine were recently published and
confirmed an OS advantage in the above population [6]. Studies are currently underway to investigate
the added value of venetoclax in AML patients treated with IC [5].
Given the financial burden of venetoclax treatment and the risk of additive toxicity when combined
with IC or HMAs, it is critically important to determine which patients will most benefit from the
addition of venetoclax [7–13]. Next-generation sequencing (NGS) is a valuable tool that can be used
to identify gene mutations conferring resistance or sensitivity to venetoclax [8,14]. For example,
patients harboring nucleophosmin 1 (NPM1) or isocitrate dehydrogenase (IDH) mutations consistently
respond well to combined venetoclax–chemotherapy treatment [9,12,15,16]. Nevertheless, there remain
limitations to NGS use, including cost and turnaround time (2–3 weeks), which hampers rapid
treatment decisions [17]. Here, we demonstrate that the analysis of BCL-2 protein level can be used as
a rapid and low-cost method to identify a subgroup of BCL-2− AML patients with high sensitivity to
standard IC or HMAs, thereby precluding the need for adding venetoclax treatment in approximately
one in five newly diagnosed AML patients.
2. Patients and Methods
2.1. Patients
This post-diagnostic study involved all newly diagnosed patients aged≥18 years with a 2016 World
Health Organization (WHO)-confirmed diagnosis of AML [18], diagnosed between 1 January 2017
and 31 December 2019 at the Antwerp University Hospital (Antwerp, Belgium). Patients with acute
promyelocytic leukemia were excluded from the study. For each patient, we collected demographic data
(age, gender, date of diagnosis, therapy received, and date of remission/relapse/death, if applicable).
Patients were risk stratified in three groups (favorable, intermediate, and adverse risk) using the
European LeukemiaNet (ELN) 2017 criteria [1] or, if there were insufficient data for ELN classification,
using the National Comprehensive Cancer Network cytogenetic risk classification [19].
2.2. Routine Laboratory Tests
In addition, the following laboratory test values, which are routinely performed at our center during
the diagnostic work-up of AML, were recorded: hemoglobin (g/dL), platelet count (×109/L), white blood
cell (WBC) and absolute neutrophil counts (×109/L), peripheral blast count (×109/L; determined by
morphology and/or flow cytometry with 1% as the threshold for positivity), bone marrow blast
percentage (determined by morphology and/or flow cytometry), presence of CD14, CD34, and CD64 on
the bone marrow blast cell population (determined by flow cytometry), HemaVision®multiplex reverse
transcriptase (RT) polymerase chain reaction (PCR) results (DNA Diagnostic, Risskov, Denmark),
the presence of internal tandem duplications (ITDs) and tyrosine kinase domain (TKD, codons 835
and 836) mutations in the fms-like tyrosine kinase 3 (FLT3) gene (determined by standard PCR fragment
analysis), peripheral blood and bone marrow Wilms’ tumor 1 (WT1) transcript levels (determined as
per our previously described methodology [20,21]), and conventional cytogenetic data.
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2.3. BCL-2 Immunohistochemistry
Bone marrow core biopsies obtained at diagnosis were collected and analyzed for BCL-2 protein
expression by immunohistochemistry (IHC), which was performed on a Dako Omnis platform
(Agilent Technologies, Santa Clara, CA, USA) using the corresponding anti-BCL-2 antibody (clone
124). The percentage of BCL-2-expressing blast cells was manually scored under a light microscope
by two independent observers (I.D.H. and A.D.) using the H-method, which is a simple, validated
semi-quantitative immunostaining score of intensity and extent [22]. Intensity was graded on a scale
of 0 to 3 (0 = absent, 1 = weak, 2 = moderate, and 3 = intense). Extent of staining was scored from 0
to 100, which refers to the percentage of blast cells staining positive for BCL-2. Intensity and extent
scores were multiplied to generate an H-score ranging from 0 to 300. Based on previous research [23],
we established an H-score of 20 as cut-off to discriminate between BCL-2− and BCL-2+ samples.
2.4. NGS
DNA was extracted from isolated bone marrow cells using the QIAamp DNA Blood Mini Kit
(QIAgen, Hilden, Germany) as per the manufacturer’s instructions. A HaloPlex Target Enrichment kit
(Agilent Technologies) was used to produce libraries of exonic regions from 29 genes (ASXL1, BCOR,
CALR, CSF3R, CBL, CEBPA, DNMT3A, ETNK1, EZH2, FLT3, IDH1, IDH2, JAK2, KMT2A, KIT, KRAS,
MPL, NPM1, NRAS, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, and ZRSR2)
from 50 ng of genomic DNA. Index-tagged libraries were then quantified using an HS Qubit dsDNA
assay (Invitrogen, Carlsbad, CA, USA) and pooled in equimolar amounts for paired-end sequencing on
an Illumina MiSeq system using a Miseq Reagent Kit (v.2.0; 500 cycles; Illumina, San Diego, CA, USA).
Data analysis was performed with SeqNext software (JSI Medical Systems, Ettenheim, Germany).
Additionally, we used Pindel (https://www.sanger.ac.uk/science/tools/pindel) to detect large FLT3
indels. FLT3 variants of inconclusive pathogenicity were considered negative. A threshold of 2% of
mutated DNA in a wild-type background was applied to ensure a sensitivity of 5%. Regions covered
by <500 reads did not fulfill the analysis requirements and were considered uninformative.
2.5. Clinical Outcome Evaluation
Patients who received at least one cycle of IC and at least four cycles of HMAs were considered
evaluable for response. Treatment response was defined as any patient under IC or HMAs who
obtained a complete remission (CR), CR with incomplete blood recovery (CRi), CR with incomplete
platelet recovery (CRp), morphologic leukemia-free state (MLFS), or partial remission (PR) on bone
marrow re-evaluation. We used the definitions of CR, CRi, CRp, MLFS, and PR as detailed in the
2017 ELN recommendations [1]. Patients who were primary refractory or experienced an early death
(defined as death during IC or within the first four HMA cycles) were categorized as non-responders.
OS was calculated from time of diagnosis until date of last follow-up or death from any cause.
2.6. Statistical Analyses
Statistical analysis and graphing were performed using SPSS (version 26.0; IBM Corp., Armonk,
NY, USA) and/or GraphPad Prism (version 8.0.2; GraphPad Software, La Jolla, CA, USA). The results
from descriptive statistics were reported as frequencies or mean values ± standard errors of the
mean (SEM). Contingency analysis with Fisher’s exact test was performed for categorical variables.
For continuous variables, Mann–Whitney (non-parametric) or unpaired Student’s t-tests (parametric)
were used depending on whether the variables failed or passed the Kolmogorov–Smirnov normality test,
respectively. Kaplan−Meier OS curve comparison was performed using the Gehan–Breslow–Wilcoxon
test. A p-value < 0.05 was considered statistically significant.
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3. Results
3.1. BCL-2 Is Heterogeneously Expressed in AML
We collected data from 112 patients consecutively diagnosed with and/or treated for AML between
1 January 2017 and 31 December 2019, at the Antwerp University Hospital, a large, tertiary academic
center in Belgium (Table 1). Ninety-three patients received a trephine biopsy at diagnosis and
were evaluable for BCL-2 protein analysis by IHC. BCL-2 was overexpressed in 72 of 93 cases
(77.4%), whereas 21 of 93 samples (22.6%) showed no or negligible expression (defined as absent or
weak expression in ≤20% of AML blasts). BCL-2 staining intensity in BCL-2+ patients was highly
heterogeneous, with H-scores ranging from 20 to 300 (Figure 1).
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Figure 1. (A) Light micrographs of BCL-2 (B-cell leukemia/lymphoma-2, left) and corresponding
haematoxylin and eosin (HE; middle) and CD34 stained paraffin sections of trephine biopsies from one
representative acute myeloid leukemia patient with a BCL-2 H-score of 300; (B) bone marrow BCL-2
immunostains from two representative patients with H-scores of 300 (left panel), 150 (middle panel),
and ≤20 (right panel). Thick black line = 50 µm.
As shown in Table 1, there were no statistically significant differences in baseline patient
demographics (age or gender) between the BCL-2− and BCL-2+ subgroups nor were there differences
in AML diagnosis (de novo AML vs. secondary AML) or AML risk profile (favorable, intermediate,
and adverse). There was also an equal frequency distribution of the four main WHO subtypes (i.e., AML
with recurrent genetic abnormalities, AML with myelodysplasia-related changes, therapy-related AML,
and AML not otherwise specified [18]) among the total patient population and the BCL-2−/BCL-2+
subgroups. AML with mutated NPM1 was the most common type within the “AML with recurrent
genetic abnormalities” category, occurring in 24% of all AML cases and in 23.8% and 23% of BCL-2−
and BCL-2+ AML cases, respectively.
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Table 1. Baseline characteristics of the BCL-2− and BCL-2+ AML subgroups.
All Patients BCL-2− BCL-2+
H-Score 0–20 H-Score 21–300
Number (%) 112 21 (22.6%) 72 (77.4%)
Median age in years (range) 65 yr (19–92 yr) 67 yr (24–87 yr) 67 yr (19–89 yr)
Male (%) 60 (53.6%) 10 (47.6%) 42 (58.3%)
Female (%) 52 (46.4%) 11 (52.4%) 30 (41.7%)
De novo AML (%) 78 (69.6%) 14 (66.7%) 49 (68.1%)
Secondary AML (%) 34 (30.4%) 7 (33.3%) 23 (31.9%)
ELN/Cytogenetic risk
Favorable 26 (25.0%) 7 (33.3%) 14 (19.7%)
Intermediate 41 (39.4%) 5 (23.8%) 32 (45.1%)
Adverse 37 (35.6%) 9 (42.9%) 25 (35.2%)
BCL-2, B-cell leukemia/lymphoma-2; AML, Acute myeloid leukemia.
3.2. BCL-2− and BCL-2+ AML Subgroups Show Similar Proliferative Activity but Different Bone Marrow
Blast Percentages
To assess BCL-2 as a marker of proliferative activity in AML subgroups, we compared the degree
of leukocytosis, as well as the presence/absence of peripheral blasts, between the BCL-2− and BCL-2+
subgroups. Despite a lower absolute value, there was no statistically significant difference in mean
WBC count in the BCL-2− subgroup as compared with the BCL-2+ subgroup (24.9 ± 8.5 × 109/L
vs. 36.3 ± 7.0 × 109/L; p = 0.7793). Additionally, six of 21 (28.6%) BCL-2− AML patients showed a
WBC count of ≥25 × 109/L, an important marker of proliferative disease [24], as compared with 24 of
72 patients (33.3%) in the BCL-2+ subgroup. Similarly, peripheral blasts were detected in 90.5% and
87.3% of BCL-2− and BCL-2+ patients, respectively. In contrast, the mean bone marrow blast percentage
was significantly lower in the BCL-2− subgroup as compared with the BCL-2+ subgroup (42.1 ± 5.1% vs.
54.9 ± 3.1%; p = 0.0472). This difference was most pronounced in patients with favorable and adverse
ELN/cytogenetic risk (p = 0.0128), whereas there was no statistically significant difference in mean
bone marrow blast percentage in the intermediate risk group. Although a previous study established a
correlation between BCL-2 expression and CD34 expression [25], our results showed that BCL-2 is not
differentially expressed among CD34− and CD34+ AML patients. The mean BCL-2 H-score among
the 27 evaluable patients with CD34− AML was 104 ± 16 versus 125 ± 11 among the 61 CD34+ AML
patients (p = 0.2990). There was a clear trend (p = 0.0859) towards lower BCL-2 expression in patients
with monocytic AML, defined here on the basis of CD64 positivity [26]. The mean BCL-2 H-score
among the 22 evaluable CD64+ AML patients was 89 ± 17 compared to 126 ± 12 in the 55 evaluable
CD64− patients. The difference was even more pronounced in the 11 evaluable patients with strong
CD64 expression, as evidenced by the mean BCL-2 H-score of 78 ± 22 in this specific subgroup.
3.3. BCL-2− AML Subgroup Is Characterized by a Distinct Molecular Signature
The Wilms’ tumor 1 (WT1) gene, whose protein product acts as a transcription factor, regulating
cell development and survival and whose quantitative assessment is a useful tool to measure disease
burden in AML [14,27,28], was overexpressed in either the peripheral blood or bone marrow in 17 of
19 (89.5%) evaluable BCL-2− AML patients and in 57 of 60 (95.0%) evaluable BCL-2+ AML patients.
In line with the lower bone marrow blast percentage, the WT1 transcript burden in the bone marrow
was significantly lower in the BCL-2− AML subgroup (47,910 ± 24,410 copies/µg) as compared with
the BCL-2+ subgroup (148,900 ± 23,700 copies/µg; p = 0.0016) (Figure 2).
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BCL-2− BCL-2+ p-Value
(H-Score 0-20) (H-Score 21-300)
DNA methylation
DNMT3A 5 (27.8%) 15 (24.6%) >0.05
TET2 4 (22.2%) 16 (26.2%) >0.05
IDH1 1 (5.6%) 6 (9.8%) n.d.
IDH2 3 (16.7%) 5 (8.2%) >0.05
Tumor suppressor
genes
TP53 3 (16.7%) 9 (14.8%) n.d.
WT1 0 (0.0%) 6 (9.8%) >0.05
Epigenetic modifiers
ASXL1 3 (16.7%) 3 (4.9%) >0.05
BCOR1 2 (11.1%) 7 (11.5%) n.d.
EZH2 0 (0.0%) 1 (1.6%) n.d.
KMT2A 0 (0.0%) 0 (0.0%) n.d.
Transcription factors
CEBPA 0 (0.0%) 6 (9.2%) n.d.
RUNX1 4 (22.2%) 9 (14.8%) >0.05
SETBP1 0 (0.0%) 0 (0.0%) n.d.




NPM1 6 (31.6%) 18 (27.7%) >0.05
Activated signaling
CBL 0 (0.0%) 0 (0.0%) n.d.
FLT3 1 (5.6%) 20 (30.8%) =0.0331
JAK2 1 (5.6%) 4 (6.6%) n.d.
KIT 0 (0.0%) 3 (4.6%) n.d.
KRAS 4 (22.2%) 1 (1.6%) n.d.
MPL 1 (5.6%) 0 (0.0%) n.d.
NRAS 0 (0.0%) 10 (16.4%) =0.0626
RNA Splicing
SF3B1 1 (5.6%) 4 (6.6%) n.d.
SRSF2 3 (16.7%) 4 (6.6%) >0.05
U2AF1 1 (5.6%) 2 (3.3%) n.d.
Cohesin complex
STAG2 2 (11.1%) 4 (6.6%) n.d.
Other
CALR 0 (0.0%) 1 (1.6%) n.d.
CSF3R, ETNK1 and
ZRSR2 0 (0.0%) 0 (0.0%) n.d.
NGS, Next-generation sequencing; n.d., not determined; testing for statistical significance was only determined for
driver gene mutations with an anticipated frequency of >10% according to Metzeler et al. [29].
3.4. Absence of BCL-2 Expression Identifies a Subgroup of AML Patients with Good Response to Chemotherapy
and Favorable OS
In the BCL-2− subgroup, 71.4% of the patients received IC and 19.0% HMAs. This was comparable
with the BCL-2+ subgroup, which was composed of 62.5% IC-treated patients and 22.2% HMA-treated
patients. The overall response rate (CR + CRi + CRp + MLFS + PR) to IC and HMAs was 94.1% (16 of
17 response-evaluable patients) in the BCL-2− subgroup, whereas it was only 61.0% (36 of 59 patients)
in the BCL-2+ subgroup (p = 0.0086).
The median OS tended to be prolonged in the BCL-2− subgroup, with nearly a doubling of the OS
time for IC-treated BCL-2− AML patients as compared to their BCL-2+ counterparts (22.2 months vs.
13.3 months; p = 0.0778). Given the underrepresentation of FLT3 mutations in the BCL-2− subgroup
and the known negative prognostic impact of FLT3-ITD, we next aimed to determine whether the
observed difference in median OS was due to the different FLT3-ITD mutational statuses between
the two subgroups. Exclusion of the FLT3-ITD+ patients had no impact on the median OS difference
between the IC-treated BCL-2− and BCL-2+ patients (22.2 months vs. 10.1 months; p = 0.0690). The OS
advantage was clearly demonstrable in favorable/intermediate risk BCL-2− AML patients (median OS
of BCL-2− vs. BCL-2+ patients: undefined vs. 18.8 months; p = 0.0411; Figure 3A). The median OS of
adverse risk BCL-2− patients was 7.4 months compared to 8.0 months in the BCL-2+ cohort (p = 0.6040;
Figure 3B).
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4. Discussion
In recent years, the anti-apoptotic protein BCL-2 has emerged as an attractive therapeutic target
in a variety of cancers, including AML [5]. The oral BCL-2 inhibitor venetoclax has shown strong
clinical activity in AML patients, in particular when combined with conventional chemotherapies [6,13].
The addition of venetoclax to standard therapy will likely become the new treatment paradigm in AML
in the very near future [5]. For pharmacoeconomic reasons and because of the risk of serious additive
toxicities, it is imperative to identify which AML patients will benefit most from the incorporation
of venetoclax into their treatment regimen. Here, we report on bone marrow BCL-2 IHC as a simple,
rapid, and low-cost method to identify a subpopulation of AML patients with no or negligible BCL-2
protein expression. This group displayed a low-risk profile on the phenotypic, molecular, and clinical
level, with good response to standard therapy, thus precluding the need for the addition of venetoclax.
There is a general assumption that BCL-2 is broadly expressed among AML patients. Our study,
which comprised a representative group of AML patients with cytogenetic and molecular characteristics
that conformed to real-world data [29], however, indicates that 1 in 5 AML patients should be considered
as BCL-2− and that there is a strong inter-patient heterogeneity, both in terms of BCL-2 staining intensity
and frequency, among the BCL-2+ patients. Using the same cut-off for positivity as applied in the
current study, Campos et al. [23] previously demonstrated BCL-2 positivity in only 34% of newly
diagnosed AML patients. Our results are more in line with the study by Bensi et al. [30], who found
evidence of BCL-2 expression (defined by the same 20% cut-off level) in 68.3% of the cases at diagnosis.
Previous work has linked BCL-2 expression in AML with distinct phenotypic features. For example,
BCL-2 expression was found to correlate with higher WBC counts at diagnosis [23], a finding that could
not be substantiated in the present study. Likewise, we were not able to demonstrate a statistically
significant difference in BCL-2 protein expression level between CD34+ and CD34− AML patients,
whereas others have shown that BCL-2 is maximally expressed in the CD34+ leukemic cell compartment,
followed by a downregulation upon the loss of CD34 during differentiation [25,31,32]. In line with
two recent studies demonstrating lower BCL-2 gene expression levels in AMLs with a monocytic
component [33,34], we observed lower BCL-2 protein levels in monocytic AML. This might, at least in
part, explain why AMLs with a monocytic phenotype tend to be more resistant to venetoclax-based
therapy. Again at the phenotypic level, this study revealed a higher percentage of bone marrow blasts
in patients with demonstrable BCL-2 expression. We believe that the prognostic relevance of this
finding is negligible, given the fact that only AML with a low blast count (i.e., 20–29%) is associated
with a more favorable prognosis; in AML with ≥30% blasts—as was the case for both the BCL-2− and
BCL-2+ subgroups—the prognostic impact of the bone marrow blast percentage at baseline has not
been clearly demonstrated [24].
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At the molecular level, the BCL-2− AML subgroup was clearly marked by a favorable prognostic
profile. Consistent with a previous study by Karakas et al. [35], who observed a correlation between
WT1 and BCL-2 transcript levels in the bone marrow, we detected lower peripheral blood and bone
marrow WT1 expression levels in BCL-2− patients. Several studies have shown that WT1 overexpression
is a poor independent prognostic marker in AML, in particular in cytogenetically normal AML [35–37].
The lower WT1 expression in the BCL-2− AML subgroup can thus be considered as an indicator of
a more favorable prognosis. In addition, whereas the NGS mutational profile of the BCL-2+ group
conformed to real-world data [29], the BCL-2− subgroup displayed an underrepresentation of FLT3
(5.3%) and NRAS (0%) mutations. The anticipated frequency of these mutations in AML is ~30%
and 15–20%, respectively [29]. Although the prognostic relevance of (N)RAS mutation remains
debatable [38–41], it is well established that the presence of FLT3-ITD, which is the most common FLT3
mutational variant, is a poor prognostic factor [42,43]. However, detailed analysis revealed that the
observed OS benefit in BCL-2− patients was not due to the lower frequency of FLT3-ITD mutations.
In line with a previous study from the pre-molecular era by Campos et al. [23], this indicates that bone
marrow BCL-2 protein expression serves as a prognostic marker independent of the molecular profile.
Importantly, the prognostic value of BCL-2 positivity was only demonstrable in patients with favorable
or intermediate ELN/cytogenetic risk. Hence, for these patients, determination of the baseline bone
marrow BCL-2 protein expression can be helpful to improve the current risk stratification and make
informed decisions about the need to proceed to allogeneic hematopoietic stem cell transplantation in
first CR.
In this study, IC or HMAs alone appeared to be sufficient to induce a CR in the BCL-2− subgroup.
Based on this observation, a standard chemotherapy approach (IC or HMAs) alone is a rational choice
of therapy in AML patients with non-detectable or marginally detectable bone marrow BCL-2 protein
expression. We believe that the added value of venetoclax is highly questionable in this particular
patient population. This, however, does not preclude the possibility that venetoclax might have
therapeutic activity even in patients without apparent BCL-2 expression. It is becoming increasingly
clear that the mutational profile at baseline is predictive of the subsequent response to anti-BCL-2
therapy [12]. For example, single agent venetoclax [11] and venetoclax used in combination with
chemotherapy [6,8,12,13] has high therapeutic activity in newly diagnosed AML patients carrying
NPM1 and IDH2 mutations. In the present study, we observed an equal distribution of NPM1 and
IDH2 mutations between BCL-2− and BCL-2+ AML patients, suggesting that BCL-2 positivity is not a
prerequisite for obtaining a response to venetoclax therapy.
To conclude, absent or low BCL-2 protein expression in the bone marrow identifies a subgroup of
AMLs with a lower bone marrow blast percentage, a favorable molecular profile and good response
to standard therapies, translating into prolonged survival. We believe that the high drug costs of
venetoclax and its potential to induce greater toxicity does not legitimize the addition of venetoclax in
this AML subgroup. This group, which represents approximately one in five newly diagnosed AML
patients, was determined according to negative BCL-2 expression through IHC analysis on trephine
biopsy obtained at diagnosis. This fast and inexpensive test can be easily applied and used in the
future to rationalize the choice of initial treatment in AML, potentially avoiding unnecessary add-on
therapy with venetoclax.
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